Drug Profile
Nemiralisib - GlaxoSmithKline
Alternative Names: [14C]-GSK2269557; GSK 2269557; GSK 2269557 ELLIPTA DPILatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics; Antibronchitics; Indazoles; Indoles; Oxazoles; Piperazines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Bronchiectasis; Chronic obstructive pulmonary disease; Immunodeficiency disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Bronchiectasis in United Kingdom (Inhalation)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (IV, Infusion)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (PO, Liquid)